<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">38735354</PMID><DateRevised><Year>2024</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1555-7162</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>May</Month><Day>10</Day></PubDate></JournalIssue><Title>The American journal of medicine</Title><ISOAbbreviation>Am J Med</ISOAbbreviation></Journal><ArticleTitle>The PAX LC Trial: A Decentralized, Phase 2, Randomized, Double-Blind Study of Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir for Long COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0002-9343(24)00271-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amjmed.2024.04.030</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Individuals with long COVID lack evidence-based treatments and have difficulty participating in traditional site-based trials. Our digital, decentralized trial investigates the efficacy and safety of nirmatrelvir/ritonavir, targeting viral persistence as a potential cause of long COVID.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The PAX LC trial (NCT05668091) is a Phase 2, 1:1 randomized, double-blind, superiority, placebo-controlled trial in 100 community-dwelling, highly symptomatic adult participants with long COVID residing in the 48 contiguous US states to determine the efficacy, safety, and tolerability of 15 days of nirmatrelvir/ritonavir compared with placebo/ritonavir. Participants are recruited via patient groups, cultural ambassadors, and social media platforms. Medical records are reviewed through a platform facilitating participant-mediated data acquisition from electronic health records nationwide. During the drug treatment, participants complete daily digital diaries using a web-based application. Blood draws for eligibility and safety assessments are conducted at or near participants' homes. The study drug is shipped directly to participants' homes. The primary endpoint is the PROMIS-29 Physical Health Summary Score difference between baseline and Day 28, evaluated by a mixed model repeated measure analysis. Secondary endpoints include PROMIS-29 (Mental Health Summary Score and all items), Modified GSQ-30 with supplemental symptoms questionnaire, COVID Core Outcome Measures for Recovery, EQ-5D-5L (Utility Score and all items), PGIS 1 and 2, PGIC 1 and 2, and healthcare utilization. The trial incorporates immunophenotyping to identify long COVID biomarkers and treatment responders.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The PAX LC trial uses a novel decentralized design and a participant-centric approach to test a 15-day regimen of nirmatrelvir/ritonavir for long COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krumholz</LastName><ForeName>Harlan M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT; Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT; Department of Health Policy and Management, Yale School of Public Health, New Haven, CT; Center for Infection and Immunity, Yale School of Medicine, New Haven, CT. Electronic address: harlan.krumholz@yale.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawano</LastName><ForeName>Mitsuaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT; Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhattacharjee</LastName><ForeName>Bornali</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center for Infection and Immunity, Yale School of Medicine, New Haven, CT; Department of Immunobiology, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caraballo</LastName><ForeName>C&#xe9;sar</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khera</LastName><ForeName>Rohan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT; Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT; Section of Health Informatics, Department of Biostatistics, Yale School of Public Health, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shu-Xia</ForeName><Initials>SX</Initials><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrin</LastName><ForeName>Jeph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coppi</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT; Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holub</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Yale Center for Clinical Investigation, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henriquez</LastName><ForeName>Yashira</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Yale Center for Clinical Investigation, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Maria A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT; Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goddard</LastName><ForeName>Theresa B</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>Yale Center for Clinical Investigation, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rocco</LastName><ForeName>Erica</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Yale Center for Clinical Investigation, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hummel</LastName><ForeName>Amy C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Yale Center for Clinical Investigation, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Mouslmani</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Putrino</LastName><ForeName>David F</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carr</LastName><ForeName>Kevin D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Trusted Medical, Middletown, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carvajal-Gonzalez</LastName><ForeName>Santos</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pfizer, Inc., Cambridge, Mass and New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charnas</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pfizer, Inc., Cambridge, Mass and New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jesus</LastName><ForeName>Magdia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pfizer, Inc., Cambridge, Mass and New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ziegler</LastName><ForeName>Frank W</ForeName><Initials>FW</Initials><Suffix>3rd</Suffix><AffiliationInfo><Affiliation>Law Offices of Barry J. Gammons, Nashville, TN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwasaki</LastName><ForeName>Akiko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Infection and Immunity, Yale School of Medicine, New Haven, CT; Department of Immunobiology, Yale School of Medicine, New Haven, CT; Howard Hughes Medical Institute, Chevy Chase, MD.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Med</MedlineTA><NlmUniqueID>0267200</NlmUniqueID><ISSNLinking>0002-9343</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical trial</Keyword><Keyword MajorTopicYN="N">Decentralized</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Nirmatrelvir/ritonavir</Keyword><Keyword MajorTopicYN="N">PROMIS-29</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>13</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>13</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>12</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38735354</ArticleId><ArticleId IdType="doi">10.1016/j.amjmed.2024.04.030</ArticleId><ArticleId IdType="pii">S0002-9343(24)00271-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>